Bio-Thera Solutions announced that its partner Biogen has received notification from the European Commission of the approval of TOFIDENCE (tocilizumab injection) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. TOFIDENCE has already been approved for marketing in China and the United States, and this approval by the European Union is expected to expand the company's international market and enhance its international influence, which will have a positive impact on its long-term operation and performance.
百奥泰：托珠单抗注射液获欧盟上市批准
Bio-Thera Solutions: The injection of Toripalimab has been approved for sale in the European Union.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.